New secondary analysis of CLEAR Outcomes data for bempedoic acid show significant risk reduction of total cardiovascular events and no increase of new-onset diabetes in patients at high-risk of cardiovascular disease
Results from a prespecified, secondary analysis of total cardiovascular (CV) events during the CLEAR Outcomes trial demonstrate that bempedoic acid, marketed as NILEMDO®▼ in Europe,...